Condition
Thrombocytopenia, Immune
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
Treatment Research
2 treatments under study, led by Vlx1005
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
50.0%
1 terminated out of 2 trials
Success Rate
0.0%
-86.6% vs benchmark
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
2Total
Phase 2 (1)
Phase 3 (1)
Trial Status
Terminated1
Not Yet Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT07455006Phase 3Not Yet RecruitingPrimary
Safety and Efficacy Study of QL0911 to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients
NCT05785819Phase 2TerminatedPrimary
A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia
Showing all 2 trials
Research Network
Common Treatments
- Vlx10051
- Ql09111
Active Sponsors
- Qilu Pharmaceutical Co., Ltd.1
- Veralox Therapeutics1
Top Investigators
Duke Clinical Research Institute
Related Conditions
- Heparin Induced Thrombocytopenia1